Evaluation of leukemic contamination in peripheral blood stem cell leukaphereses vs bone marrow after consolidation therapy in acute myeloid leukemia: Not a critical factor in outcome?

Haematologica

Volumn 88, Issue 6, 2003, Pages 715-718

  Melillo, Lorella ^a,c   Specchia, Giorgina ^d   Ferrara, Felicetto ^b   Minervini, M Marta ^a   Pastore, Domenico ^d   Carella, Angelo M ^a  

^a IRCCS   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

^c CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^d NONE

Author keywords

Acute myeloid leukemia; Leukemic contamination; Outcome

Indexed keywords

CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTAMINATION; CYTOGENETICS; EVALUATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; KARYOTYPE; LEUKAPHERESIS; LEUKEMIA CELL; MALE; PROGNOSIS; STEM CELL; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; BONE MARROW TRANSPLANTATION; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; LEUKAPHERESIS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0037788269     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Korbling M, Fliedner TM, Holle R. Autologous blood stem cell (ABSCT) vs purged bone marrow transplantation (pABMT) in standard risk AML: influence of source and cell composition of the autograft on hemopoietic reconstitution and disease-free survival. Bone Marrow Transplant 1991;7:343-9.
2. To LB, Russel J, Moore S, Juttner CA. Residual leukemia cannot be detected in very early remission peripheral blood stem cell collection in acute non-lymphoblastic leukemia. Leukemia Res 1987;11:327-9.
3. Carella AM, Dejana A, Lerma E, Podestȧ M, Benvenuto F, Chimirri F, et al. In vivo mobilization of karyotypically normal peripheral blood progenitor cells in high-risk MDS, secondary or therapy-related acute myelogenous leukemia. Br J Haematol 1996;95:127-30.
4. Mehta J, Powles R, Singhal S, Treleaven J. Peripheral blood stem cells transplantation may result in increased relapse of acute myeloid leukemia due to reinfusion of a higher number of malignant cells. Bone Marrow Transplant 1995;15:652-3.
5. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC 10 Trial. Blood 1998;92:2322-33.
6. Kusec R, Laczika K, Knobl P, Friedl J, Greinix H, Kalhs P, et al. AML1/ETO fusion mRNA can be detected in remission blood samples of all patients with t (8;21) acute myeloid leukemia after chemotherapy or autologous bone marrow transplantation. Leukemia 1994;8:736-9.
7. Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, et al. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARa fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. Blood 1998;92:784-9.
8. Laczika K, Novak M, Hilgarth B, Mitterbauer M, Mitterbauer G, Scheidel-Petrovic A, et al. Competitive CBFβ-MYH11 reverse-transcriptase polymerase chain reaction for quantitative assessment of minimal residual disease during postremission therapy in acute myeloid leukemia with inversion (16): a pilot study. J Clin Oncol 1998;16:1519-25.
9. Van Dongen JJM, Macintyre EA, Gabert JA, Elabesse E, Rossi V, Saglio G, et al. Standardized RT-PCR analysis of fusion genes transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia 1999;13: 1901-28.
10. th UK MRC AML trial. Bone Marrow Transplant 1997; 19:1117-23.